Latest Options News

Astron Corporation has completed its redomicile from Hong Kong to Australia, launching Astron Limited (Aus NewCo) as the new ASX-listed parent company with a 2-for-1 share consolidation.

Elixinol Wellness has launched its Healthy Chef Protein Water range, entering Australia’s rapidly expanding $499 million protein supplements market with a clean-label, functional beverage lineup.

WAM Strategic Value Limited has declared an increased fully franked dividend following an 8.6% rise in its investment portfolio for FY2025, showcasing resilience amid market volatility.

Centaurus Metals Limited has updated the timetable for its $3 million Share Purchase Plan, offering eligible shareholders in Australia and New Zealand shares at $0.36 each with free-attaching options exercisable at $0.50.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Redcastle Resources has partnered with BML Ventures to fast-track gold production at key deposits while massively expanding its Eastern Goldfields footprint through a strategic tenement acquisition.

Magnetite Mines has launched a $2.65 million renounceable rights issue with increased underwriting support, following promising rare earth mineralisation findings at its Ironback Hill Project.

Vicinity Centres confirms its distribution reinvestment plan will apply to the FY25 final distribution, offering investors a 1% discount on new securities issued under the plan.

Marquee Resources has successfully closed an oversubscribed $2.51 million placement, underscoring strong investor confidence as it prepares for the next phase of drilling at its Mt Clement Antimony Project.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

EV Resources has signed a strategic Memorandum of Understanding with Wogen Resources and Xcelsior Capital Advisors to fund and advance its Los Lirios Antimony Project in Mexico, aiming to establish a 100 tonne-per-day processing plant.

Neurizon Therapeutics reports encouraging topline results from its Phase 1 Open-Label Extension study of NUZ-001, demonstrating long-term safety and a significant survival advantage in ALS patients. These findings pave the way for the pivotal HEALEY ALS Platform Trial planned for late 2025.